Ocugen (OCGN) Cash & Equivalents (2014 - 2026)

Ocugen (OCGN) has 12 years of Cash & Equivalents data on file, last reported at $37.8 million in Q1 2025.

• Quarterly Cash & Equivalents rose 43.32% year-over-year to $37.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $37.8 million (up 43.32% YoY) and the FY2023 annual result came in at $39.5 million, down 49.12% from the prior year.
• Cash & Equivalents rose to $37.8 million in Q1 2025, from $15.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $129.8 million in Q1 2022 to a low of $15.7 million in Q2 2024.
• A 5-year average of $73.2 million and a median of $70.6 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 1302.82% — and 2024, when it tumbled 77.76%.
• Tracing OCGN's Cash & Equivalents over 5 years: stood at $95.0 million in 2021, then declined by 18.32% to $77.6 million in 2022, then plunged by 49.12% to $39.5 million in 2023, then plunged by 60.22% to $15.7 million in 2024, then surged by 140.81% to $37.8 million in 2025.
• The last three Cash & Equivalents figures came in at $37.8 million (Q1 2025), $15.7 million (Q2 2024), and $26.4 million (Q1 2024), per Business Quant data.